Comparison · NCT00432094-e829e473
2 Transplants vs 1 Transplant: Engraftment of Neutrophils
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. 2 Transplants vs 1 Transplant: Engraftment of Neutrophils. Trial comparisons, record NCT00432094-e829e473. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00432094-e829e473
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.929 | 0.685 | 0.987 | wilson | |
| Risk in group 2 | 1 | 0.701 | 1 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0714 | -0.315 | 0.233 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.929 | 0.803 | 1.07 | log | |
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to treat, for one fewer participant with the outcome on 2 Transplants than on 1 Transplant | 14 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | 2 Transplants | Patients with Germ Cell Tumors (GCT) treated with a second tandem autologous stem cell transplant (AuSCT) with non-cross-resistant conditioning regimens.~carboplatin: Days -6, -5, -4: 500mg/m2\^/day intravenously (IV) over 60 minutes~etoposide: 600mg/m\^2/day intravenously (IV) over 60 minutes on Days -6 through -3.~thiotepa: 150mg/m\^2/day intravenously IV over 30 minutes; Days -6, -5 and -4~autologous hematopoietic stem cell transplantation: Peripheral blood stem cell infusion (\< 4 x 10\^6 CD34+ cells/kg)~filgrastim: Beginning Day 5, G-CSF 5 μg/kg/day until absolute neutrophil count (ANC) ≥ 1500/UL for 3 consecutive days. | 13 | 14 | OG000 |
| Group 2 | 1 Transplant | Patients with Germ cell tumors who receive one transplant only.~ifosfamide: 2500 mg/m\^2/day continuous infusion intravenously on Days -6, -5 and -4.~paclitaxel: 225 mg/m\^2 intravenous over 3 hours on Day -7.~autologous hematopoietic stem cell transplantation: Peripheral blood stem cell infusion (\< 4 x 10\^6 CD34+ cells/kg)~Mesna: 2500 mg/m\^2/day continuous infusion intravenously on Days -6, -5 and -4.~filgrastim: Beginning Day 5, G-CSF 5 μg/kg/day until absolute neutrophil count (ANC) ≥ 1500/UL for 3 consecutive days. | 9 | 9 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Engraftment of Neutrophils
- Description
- Neutrophil engraftment is defined as the first day of three consecutive days where the neutrophil count (absolute neutrophil count) is 500 cells/mm3 (0.5 x 109/L) or greater.
- Time frame
- Day 42
- Population
- The protocol is essentially one single-arm, but patients received either one or two transplants depending on the cells they had available and we are reporting results for these two groups.
Source ClinicalTrials.gov
Trial
- Title
- Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors
- NCT number
- NCT00432094
- Phases
- PHASE2
- Conditions
- Childhood Germ Cell Tumor, Ovarian Cancer, Teratoma
- Interventions
- carboplatin, etoposide, ifosfamide, paclitaxel, thiotepa, autologous hematopoietic stem cell transplantation, Mesna, filgrastim
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Results first posted
- 2022-05-17
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00432094?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00432094-e829e473